Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial
Adjuvant sunitinib has significantly improved disease-free survival versus placebo in patients with renal cell carcinoma at high risk of recurrence post-nephrectomy.11/14/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 14, 2018 Category: Urology & Nephrology Source Type: news

MDACC 2018: Debate: Is There Still a Role for Cytoreductive Nephrectomy in the Setting of Metastatic Renal Cell Carcinoma?
Dr. Jose Karam explains the role of cytoreductive nephrectomies when patients have metastatic kidney cancer.11/12/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 12, 2018 Category: Urology & Nephrology Source Type: news

Sunitinib Alone or after Nephrectomy in Renal Cancer
In the CARMENA (Cancer du Rein Metastatique Nephrectomie et Antiangiog éniques) trial, Méjean et al. (Aug. 2 issue)1 determine the noninferiority of sunitinib alone, as compared with nephrectomy followed by sunitinib, on the basis of the observation that the 95% confidence interval for the hazard ratio of death did not exceed 1.20 (the noninferiority margin for t he trial).11/09/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 9, 2018 Category: Urology & Nephrology Source Type: news

Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy
Despite the evolution of systemic therapy from the immunotherapy to targeted therapy eras, surgical management remains a mainstay of treatment of patients with locally advanced, lymph node-positive, and distant metastatic renal cell carcinoma.11/07/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 7, 2018 Category: Urology & Nephrology Source Type: news

Sunitinib vs Nephrectomy Followed by Sunitinib in Metastatic Renal Cell Carcinoma
In an interim analysis of the French phase III noninferiority Carmena trial reported in The New England Journal of Medicine, Arnaud M éjean, MD, PhD, of the Hôpital Européen Georges Pompidou, and colleagues found that sunitinib alone was not inferior in overall survival vs nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic clear cell renal cell carcinoma.10/30/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - October 30, 2018 Category: Urology & Nephrology Source Type: news

Partial Nephrectomy Linked to Improved OS in T1a RCC
A study shows T1a RCC patients have improved overall survival when receiving partial nephrectomy compared with radical nephrectomy. (Source: CancerNetwork)
Source: CancerNetwork - October 4, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

The Effect of a Therapeutic Pillow on Pain After Nephrectomy The Effect of a Therapeutic Pillow on Pain After Nephrectomy
The use of a therapeutic pillow may help improve discomfort and pain after nephrectomy.Urologic Nursing (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 28, 2018 Category: Consumer Health News Tags: Nursing Journal Article Source Type: news

Susan describes her cancer diagnosis at age 25
Susan from Alberta, Canada, was diagnosed with stage 1 kidney cancer at age 25. After receiving a radical right nephrectomy, she has remained cancer-free for 12 years. Below, Susan shares her best advice for those going through a similar situation: 1.) Ask questions and record everything so you can remember what the doctor says. It will also serve as a journal for you down the road. 2.) Be kind to yourself. There will be bad days, hard days, but there will be many good days as well so enjoy those when they come. 3.) Let your close loved ones know when you are having a bad day, don ’t keep your feelings to yourself...
Source: Kidney Cancer Association - September 20, 2018 Category: Urology & Nephrology Source Type: news

NLR Predicts Survival After Cytoreductive Nephrectomy+Thrombectomy
Preoperative neutrophil-lymphocyte ratio (NLR) may predict survival following cytoreductive nephrectomy plus thrombectomy for renal cell carcinoma (RCC), a new study suggest.09/19/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 19, 2018 Category: Urology & Nephrology Source Type: news

Case Report Describes 4 Breast Cancer Cases Post Transplant
Single donor transmitted cancer to four recipients; one survived after transplant nephrectomy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 11, 2018 Category: Cancer & Oncology Tags: Oncology, Surgery, Journal, Source Type: news

Dawnia survives kidney cancer after receiving a nephrectomy on her right kidney
Five years ago, Dawnia, who lives in Texas, was diagnosed with stage II kidney cancer at age 50. During a routine visit at her gynecologist ’s office, the nurse practitioner was alarmed when she learned that Dawnia’s mother was recently diagnosed with kidney cancer. The nurse urged her to get an ultrasound which showed a 9×9 tumor. Dawnia credits her nurse practitioner’s suggestion of getting an ultrasound with saving her life. S he has remained cancer-free following her nephrectomy. No chemotherapy or radiation was required. Dawnia had chest x-rays and abdominal CT scans every three to six months f...
Source: Kidney Cancer Association - September 11, 2018 Category: Urology & Nephrology Source Type: news

"Kidney Cancer" Journal Release New Issue
The newest issue of the journal, “Kidney Cancer” just came out! The issue includes two review articles on the topics of diagnostic imaging and adjuvant therapy, a commentary about partial nephrectomy and five research articles, plus a new Clinical Trials Corner.08/24/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 24, 2018 Category: Urology & Nephrology Source Type: news

VTE Risk May Hurt Survival After Kidney Cancer Surgery
All-cause mortality was significantly higher among renal cell carcinoma (RCC) patients who developed symptomatic venous thromboembolism (VTE) after undergoing nephrectomy and inferior vena cava (IVC) tumor thrombectomy (TT) accompanied by intravascular tumor thrombosis, a retrospective analysis showed.08/20/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 20, 2018 Category: Urology & Nephrology Source Type: news

Sunitinib vs Nephrectomy Followed By Sunitinib In Metastatic Renal Cell Carcinoma
In an interim analysis of the French phase III noninferiority Carmena trial reported in The New England Journal of Medicine, M éjean et al found that sunitinib alone was not inferior in overall survival vs nephrectomy followed by sunitinib in patients with intermediate- or poor-risk metastatic clear cell renal cell carcinoma.08/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news

Results From The Carmena Trial
Arnaud M éjean, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses his study’s potentially practice-changing finding that nephrectomy is no longer the standard of care for patients with metastatic renal cell carcinoma (Abstract LBA3).08/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news

Dr. Drake On The Role of Cytoreductive Nephrectomy In RCC
Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia ’s Cancer Immunotherapy Programs, discusses the role of cytoreductive nephrectomy in the treatment of patients with renal cell carcinoma (RCC).08/08/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 8, 2018 Category: Urology & Nephrology Source Type: news

Cytoreductive Nephrectomy May Still Remain Standard For Some With Metastatic Renal Cell Carcinoma
The addition of cytoreductive nephrectomy to treatment with sunitinib malate did not provide a survival benefit for intermediate and poor-risk patients with metastatic renal cell carcinoma, according to results of the phase 3 CARMENA clinical trial presented at ASCO Annual Meeting.08/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 6, 2018 Category: Urology & Nephrology Source Type: news

Patients With Early Kidney Cancer Benefit From Robotic Partial Nephrectomy
A comprehensive study by the Keck School of Medicine of USC, which has found that robotic partial nephrectomy offers significantly better patient outcomes.07/26/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 26, 2018 Category: Urology & Nephrology Source Type: news

mRCC: Cytoreductive Nephrectomy in the Modern Era
Walter Stadler, M.D., who is on our medical steering committee, is one of the panelists in this video.07/26/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 26, 2018 Category: Urology & Nephrology Source Type: news

Good results seen with laparoscopic partial nephrectomy following selective embolization of tumor
The short-term oncological and functional outcomes for partial nephrectomy are comparable for laparoscopic partial nephrectomy following selective embolization of tumor (LPNE) in a hybrid operating room and robot-assisted partial nephrectomy (RAPN). A longer follow-up and a larger cohort of patients would be necessary to verify the benefits of LPNE, which appears to be a very interesting alternative to RAPN.07/25/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 25, 2018 Category: Urology & Nephrology Source Type: news

Poorer RCC outcomes with incidental upstaging after partial nephrectomy
Patients with incidental pathologic T3a (pT3a) upstaging after partial nephrectomy (PN) have significantly reduced recurrence-free survival (RFS) and cancer-specific survival (CSS) when compared to patients whose disease isn't upstages from pT1a-b.07/25/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 25, 2018 Category: Urology & Nephrology Source Type: news

Patients with early kidney cancer see significant benefits with robotic partial nephrectomy
A comprehensive study by the Keck School of Medicine of USC has found that robotic partial nephrectomy offers significantly better patient outcomes.07/11/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 13, 2018 Category: Urology & Nephrology Source Type: news

nts with early kidney cancer see significant benefits with robotic partial nephrectomy
A comprehensive study by the Keck School of Medicine of USC has found that robotic partial nephrectomy offers significantly better patient outcomes.07/11/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 11, 2018 Category: Urology & Nephrology Source Type: news

Patients with early kidney cancer benefit from robotic partial nephrectomy
(University of Southern California - Health Sciences) A comprehensive study by the Keck School of Medicine of USC has found that robotic partial nephrectomy offers significantly better patient outcomes as compared with open or laparoscopic techniques. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 10, 2018 Category: International Medicine & Public Health Source Type: news

Percutaneous Ablation Provides Good Outcomes in T1a Renal Cancer Percutaneous Ablation Provides Good Outcomes in T1a Renal Cancer
For well-selected older adults, percutaneous ablation may result in oncologic outcomes similar to those of nephrectomy with fewer periprocedural complications, a population-based analysis suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Smaller Surgery for Smaller Kidney Tumors
(MedPage Today) -- Similar survival for percutaneous ablation, radical nephrectomy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 26, 2018 Category: Hematology Source Type: news

Study Compares Treatment Options for T1a Renal Cancer
Percutaneous ablation compared with partial, radical nephrectomy for 4,310 patients aged ≥ 66 years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 26, 2018 Category: Cancer & Oncology Tags: Internal Medicine, Nephrology, Oncology, Radiology, Surgery, Urology, Journal, Source Type: news

Study Compares Treatment Options for T1a Renal Cancer
TUESDAY, June 26, 2018 -- Percutaneous ablation (PA) is associated with oncologic outcomes that are similar to those of radical nephrectomy (RN) and may be associated with fewer complications than nephron-sparing partial nephrectomy (PN) for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 26, 2018 Category: Pharmaceuticals Source Type: news

More Frequent Use of Partial Nephrectomy May Benefit Kidney Cancer Patients
To evaluate trends in the use of partial nephrectomy in the United States, researchers collected information about more than 48,000 patients with non-metastatic kidney cancer treated between 1998 and 2007.06/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 13, 2018 Category: Urology & Nephrology Source Type: news

Can mRCC Patients Be Spared Debulking Nephrectomy?
In this video,Dr. Daniel George discusses CARMENA, which asked if cytoreductive surgery is necessary in the age of active systemic therapy for mRCC. (Source: CancerNetwork)
Source: CancerNetwork - June 13, 2018 Category: Cancer & Oncology Authors: Daniel George, MD Source Type: news

ASCO: Sunitinib Alone Noninferior in Metastatic Renal Cell Cancer
Sunitinib alone noninferior to nephrectomy plus sunitinib with respect to overall survival (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 5, 2018 Category: Cancer & Oncology Tags: Nephrology, Oncology, Pharmacy, Surgery, Conference News, Source Type: news

ASCO: Sunitinib Alone Noninferior in Metastatic Renal Cell Cancer
MONDAY, June 4, 2018 -- For patients with metastatic renal cell carcinoma classified as having intermediate or poor prognostic risk, sunitinib alone is noninferior to nephrectomy and sunitinib, according to a study published online June 3 in the New... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 4, 2018 Category: Pharmaceuticals Source Type: news

Patient and Tumor Features Predicted RCC Outcomes Post Nephrectomy
Routinely available patient and tumor features accurately predicted the risk progression and death from RCC post nephrectomy, a Mayo Clinic team found. (Source: CancerNetwork)
Source: CancerNetwork - May 9, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Certain Patient Subgroups May Benefit from Partial vs Radical Nephrectomy
In this large Chinese study, in certain subgroups cancer-specific survival outcomes were better with partial rather than radical nephrectomy. (Source: CancerNetwork)
Source: CancerNetwork - March 7, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Certain RCC Subgroups May Benefit From Partial vs Radical Nephrectomy
In a large Chinese study, in certain RCC subgroups cancer-specific survival outcomes were better with partial rather than radical nephrectomy. (Source: CancerNetwork)
Source: CancerNetwork - March 7, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Determinant factors for chronic kidney disease after partial nephrectomy
(Rapamycin Press) Minimally invasive surgery appears to offer broader therapeutic scope for the renal masses without compromising oncological outcomes in proper hands. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 6, 2018 Category: International Medicine & Public Health Source Type: news

45-Year-Old Female With Gross Hematuria Post Partial Nephrectomy
A 45-year-old female presents with gross hematuria 5 days after a laparoscopic partial nephrectomy for renal cell cancer. What is your diagnosis? (Source: CancerNetwork)
Source: CancerNetwork - March 1, 2018 Category: Cancer & Oncology Authors: Brian Morse, MD Tags: Image IQ Source Type: news

Analysts: Japan approves 12 new procedures for Intuitive Surgical ’ s da Vinci
Intuitive Surgical (NSDQ:ISRG) recently won approval for an additional 12 procedures in Japan using its da Vinci robot-assisted surgery devices, according to analysts at Leerink Partners. The approvals could represent an additional 200,000 cases in Japan, up from 30,000, Leerink analysts Richard Newitter and Jaime Morgan wrote this morning in a note to investors, citing talks with management, company reports and Leerink Partners estimates. Previously only cleared for prostatectomy and nephrectomy in Japan, da Vinci is now approved for additional colorectal, gynecological and thoracic surgeries, plus gastrect...
Source: Mass Device - January 18, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Regulatory/Compliance Robotics Wall Street Beat Intuitive Surgical Source Type: news

Trunk Imaging Tied to Higher Nephrectomy Risk (CME/CE)
(MedPage Today) -- More kidney removal in places with high abdominal/chest CT rates (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 28, 2017 Category: Hematology Source Type: news

FDA Approves First Adjuvant Therapy for Renal Cell Carcinoma
The FDA has approved sunitinib malate (Sutent) as an adjuvant therapy for adults at risk for recurrent renal cell carcinoma following nephrectomy. Sunitinib, a kinase... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 20, 2017 Category: Primary Care Source Type: news

FDA Approves Adjuvant Sunitinib for High-Risk RCC
The FDA has approved sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma (RCC) who have received nephrectomy and are high risk for recurrence.11/30/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - November 19, 2017 Category: Urology & Nephrology Source Type: news

Pfizer receives FDA approval for SUTENT ® (sunitinib malate) as first and only adjuvant treatment for adult patients at high risk of recurrent renal cell carcinoma
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney). (Source: World Pharma News)
Source: World Pharma News - November 16, 2017 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Robotic Radical Nephrectomy Becoming More Common
And robotic laparoscopy for rectal cancer resection does not reduce risk for conversion to open surgery (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 26, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Nephrology, Oncology, Surgery, Journal, Source Type: news

Sunitinib Has No Survival Benefit in Renal-cell Carcinoma, May Limit Late Recurrence Sunitinib Has No Survival Benefit in Renal-cell Carcinoma, May Limit Late Recurrence
Adjuvant treatment of renal-cell carcinoma (RCC) after nephrectomy with sunitinib has produced no increase in overall survival, but the treatment results in less distant disease recurrence and a higher rate of disease-free survival, according to the latest data from the S-TRAC study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 5, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Positive Surgical Margins in RCC More Common Among African Americans
African American patients with localized renal cell carcinoma who underwent robotic partial nephrectomy were at an increased risk for positive surgical margins compared with white patients. (Source: CancerNetwork)
Source: CancerNetwork - August 14, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Could SBRT Have Role in Metastatic Kidney Cancer?
This video examines a pilot trial that tested stereotactic body radiotherapy plus nephrectomy in patients with renal cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - June 28, 2017 Category: Cancer & Oncology Authors: Thomas Schwaab, MD, PhD Tags: News Renal Cell Carcinoma Videos Genitourinary Cancers Source Type: news

1 out of 200 kidney surgery recipients DIE in just 30 days after the procedure, new study warns
(Natural News) A recent analysis published in the journal BJU International revealed that all forms of kidney surgery were associated with a slight increase in 30-day mortality. As part of the study, a team of British researchers pooled data from the British Association of Urological Surgeons National Nephrectomy Audit with a total cohort population of more than 21,000 kidney... (Source: NaturalNews.com)
Source: NaturalNews.com - May 13, 2017 Category: Consumer Health News Source Type: news

Analysis examines mortality risks after different types of kidney surgery
(Wiley) A new study provides insights into the true risks of all types of nephrectomy, or surgical removal of the kidney. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 5, 2017 Category: Global & Universal Source Type: news

Your participation in this research project can help ensure that the company ’s brochure and other materials are relevant to patients
A major pharmaceutical manufacturer has commissioned market research to help improve its communications directed toward Renal Cell Carcinoma (RCC) patients.Your participation in this research project can help ensure that the company’s brochure and other materials are relevant to patients’ concerns and expressed in a clear and comprehensible way.Fieldwork, an independent healthcare research and consulting firm located in the U.S., has been engaged to conduct these research interviews on pharmaceutical manufacturer’s behalf. The research project consists of a one-time telephone interview lasting 60 minutes....
Source: Kidney Cancer Association - February 23, 2017 Category: Urology & Nephrology Source Type: news